Discussion of all aspects of biological molecules, biochemical processes and laboratory procedures in the field.
7 posts • Page 1 of 1
I'm new on board,
I'm a molecular biologist and interested in biotechnological drugs.
I hope somebody here can help me in understanding BLA vs NDA.
FDA approved some monoclonal antibody drugs, the list includes gemituzumab, efalizumab, palivizumab, daclizumab etc. Gemituzumab is listed as NDA but others as BLA, why?
can anyone help?
From an NCI source:
"After clinical trials have shown that the new agent is safe and effective, there is reason to make the agent generally available to patients and physicians. The formal process in the U.S. by which this occurs is the approval by FDA of a marketing application (New Drug Application for cytotoxic/cytostatic agents or a Biologic License Application for biological agents) submitted by a private firm; as noted previously, NCI does not submit NDAs or BLAs since it does not market products. The applicant seeks approval from FDA for one or more specific indication(s). Review and approval of an NDA or BLA are based on the demonstration of safety and efficacy assessed from detailed reports of the clinical trials; particularly randomized controlled studies. The contribution of a new agent in the treatment of a disease is demonstrated unambiguously if the agent is the only variable between the treatments."
Any drugs should fall under the NDA; antibodies may (or sometimes may not) fall under the BLA rules.
Any synthetic, small molecule used as a drug needs an NDA approval before it can be marketed. The NCI is concerned with cancers, so its language was with reference to cytotoxic/cytostatic agents. The same applies to antibiotics or anti-inflammatory or cardiac drugs, but the NCI doesn't typically deal with these disease areas.
but if we say biological products are not cytotoxic/cytostatic, so they don't need NDA, they need BLA, why this drug, gemtuzumab (monoclonal antibody) is NDA but other monoclonal antibodies are BLA?
I'll add something below that I take from fda.gov
"In june 30, 2003 FDA transferred some of the therapeutic biological products that had been reviewed and regulated by the Center for Biologics Evaluation and Research (CBER) to the Center for Drug Evaluation and Research (CDER).
Categories of Biological Products Transferred to CDER
Monoclonal antibodies for in vivo use.
Proteins intended for therapeutic use, including cytokines (e.g. interferons), enzymes (e.g. thrombolytics), and other novel proteins, except for those that are specifically assigned to CBER (e.g., vaccines and blood products). This category includes therapeutic proteins derived from plants, animals, or microorganisms, and recombinant versions of these products.
Immunomodulators: proteins or peptides that are not antigen specific (e.g., cytokines, growth factors, chemokines, etc.) that are intended to treat disease by inhibiting or modifying a pre-exisiting immune response; and proteins or peptides intended to act in antigen-specific fashion to treat or prevent autoimmune diseases by inhibiting or modifying pre-existing immune responses.
Growth factors, cytokines, and monoclonal antibodies intended to mobilize, stimulate, decrease or otherwise alter the production of cells in vivo.1 This category includes growth factors, cytokines, and monoclonal antibodies, as well as non-biological agents, administered as mobilizing agents for their direct therapeutic effect on the recipient, as well as growth factors, cytokines, and monoclonal antibodies administered for the purpose of subsequently harvesting the mobilized, stimulated, decreased or otherwise altered cells for use in a human cellular or tissue-based product (HCT/P).
Categories of Biological Products Remaining in CBER
Cellular products, including products composed of human, bacterial or animal cells (such as pancreatic islet cells for transplantation), or from physical parts of those cells (such as whole cells, cell fragments, or other components intended for use as preventative or therapeutic vaccines).
Gene therapy products. Human gene therapy/gene transfer is the administration of nucleic acids, viruses, or genetically engineered microorganisms that mediate their effect by transcription and/or translation of the transferred genetic material, and/or by integrating into the host genome. Cells may be modified in these ways ex vivo for subsequent administration to the recipient, or altered in vivo by gene therapy products administered directly to the recipient.
Vaccines and vaccine-associated products: products, regardless of their composition or method of manufacture, intended to induce or enhance a specific immune response to prevent or treat a disease or condition, or to enhance the activity of other therapeutic interventions.
Allergenic extracts used for the diagnosis and treatment of allergic diseases and allergen patch tests.
Antitoxins, antivenins, and venoms
Blood, blood components, plasma derived products (for example, albumin, immunoglobulins, clotting factors, fibrin sealants, proteinase inhibitors), including recombinant and transgenic versions of plasma derivatives, (for example clotting factors), blood substitutes, plasma volume expanders, human or animal polyclonal antibody preparations including radiolabeled or conjugated forms, and certain fibrinolytics such as plasma-derived plasmin, and red cell reagents.
Human cells, tissues and cellular and tissue-based products (HCT/P’s). This category includes HCT/P’s containing cells that have been harvested following in vivo administration of a CDER-regulated growth factor, cytokine, or monoclonal antibody,2 as well as HCT/P’s requiring ex vivo manipulation.
1CBER reviews and regulates some products other than growth factors, cytokines, and monoclonal antibodies that are mobilizing agents in that they are administered in vivo for mobilizing, stimulating, decreasing or otherwise altering the production or function of cells or tissues that are subsequently harvested for use in an HCT/P. The mobilizing agents and other cell manipulating agents reviewed and regulated by CBER also fall into one of the categories of products currently assigned to CBER (e.g., a vaccine or gene therapy).
2The most efficient way to investigate an HCT/P developed from cells that have been harvested following in vivo administration of a growth factor, cytokine, or monoclonal antibody would ordinarily be to first investigate the safety and activity of the growth factor, cytokine, or monoclonal antibody in mobilizing, stimulating, decreasing or otherwise altering cells in vivo, and then to reference this information in a subsequent application to CBER for the HCT/P. The Center jurisdiction officers listed below are available to discuss the various options and appropriate regulatory approaches.
Gemtuzumab contains a cytotoxic drug that is being directed to the tumor by the mcAb to which it is conjugated. Most likely it is the use of the cytotoxic drug that requires the NDA. All of the other agents you list are strictly antibodies and, as such, are biological agents only. I suspect most uses of antibodies will be covered under the BLA rules.
I come to write the same thing, I search for the mechanism and see ozogamicin, a chemotherapy drug, now I understand
happy to see the same opinion,
7 posts • Page 1 of 1
Who is online
Users browsing this forum: No registered users and 1 guest